Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) is leveraging artificial intelligence, epigenetics, and genetics to improve the early detection and diagnosis of coronary heart disease through its blood-based Epi+Gen CHD and PrecisionCHD tests. The company addresses a cardiovascular disease market projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050, according to the press release.
The company’s proprietary AI-driven Multi-Omics Engine analyzes genetic and epigenetic biomarkers to assess heart attack risk and identify coronary heart disease, including certain nonobstructive forms that conventional diagnostic methods may miss. This capability is critical because standard tests often fail to detect early-stage or nonobstructive coronary artery disease, which can still lead to major cardiac events.
Cardio Diagnostics has strengthened its commercialization efforts through securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, expanding U.S. provider partnerships as well as launching its first international expansion in India. These milestones are pivotal for widespread adoption, as reimbursement is a key barrier for novel diagnostic tests. The company’s ability to secure these codes signals validation from regulatory and payer entities.
With a proprietary, AI-driven platform with reimbursement milestones, growing provider adoption and evidence supporting the ability to detect what traditional tools miss, the company occupies a position that is scientifically grounded and commercially actionable in the diagnostics landscape. The implications of this announcement are significant: if Cardio Diagnostics’ tests become standard, they could reduce the burden of cardiovascular disease by enabling earlier intervention, potentially saving lives and reducing healthcare costs.
For more information, visit the company’s newsroom at https://nnw.fm/CDIO or the full article at https://nnw.fm/9LJ2r.
